Open an account

Hims & Hers Health

HIMS · NYSE

$29.21+$1.06 (+3.77%)TodayMarket closed ·
Prev close $28.15

About HIMS

Hims & Hers Health, Inc. operates a telehealth consultation platform. The company is headquartered in San Francisco, California and currently employs 2,442 full-time employees. The company went IPO on 2019-09-09. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. The company connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. The company also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.

Employees
2,442
Headquarters
San Francisco, California
Listed
Sep 9, 2019
Sector
Health Care
Industry
Health Care Providers & Services
Website
forhims.com

HIMS key statistics

Market cap
6.57B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
10.94M
Volume
8.46M
Open price
$28.00
High today
$30.02
Low today
$27.75
52 Week high
$63.63
52 Week low
$13.74

Hims & Hers Health (HIMS) at a glance

Hims & Hers Health (HIMS) last traded at $29.21, with a market cap of 6.57B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $27.75 and $30.02. The current price is 5.3% above the day's low and 2.7% below its high.

Volume so far is 8.46M shares, below the average of 10.94M shares a day.

Over the past year Hims & Hers Health has ranged from $13.74 to $63.63, and now sits 31% of the way up that range.

Hims & Hers Health met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.37 per share against an estimate of -$0.0143.

The average analyst price target is $32.05, 9.7% above the current price, from 14 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

21%of 14 analyst ratings say Buy
  • Buy21.4%
  • Hold78.6%
  • Sell0.0%
Price target · 16 analystsAvg $32.05
Low
$23.69
Now
$29.21
High
$44.10

HIMS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 163.2% on average.

  1. Q3 FY24: reported $0.32 per share against an estimate of $0.0417
  2. Q4 FY24: reported $0.11 per share against an estimate of $0.1051
  3. Q1 FY25: reported $0.20 per share against an estimate of $0.1233
  4. Q2 FY25: reported $0.17 per share against an estimate of $0.1541
  5. Q3 FY25: reported $0.06 per share against an estimate of $0.1063
  6. Q4 FY25: reported $0.08 per share against an estimate of $0.0467
  7. Q1 FY26: reported -$0.19 per share against an estimate of $0.0442
  8. Q2 FY26: reported -$0.37 per share against an estimate of -$0.0143

HIMS news

  • Press releaseGlobe Newswire

    Bragar Eagel & Squire, P.C. Reminds Hims & Hers Health, Inc. Investors of the Upcoming Lead Plaintiff Deadline and Urges Investors to Contact the Firm Before November 2nd

  • Press releasePRNewswire

    What's Next for Hims & Hers Health, Inc. Shareholders After 14.73% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline

  • Press releasePRNewswire

    Hims & Hers Health (NYSE: HIMS) Facing Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower

  • Press releaseNewsfile

    Kaplan Fox Encourages Hims & Hers Health, Inc. (HIMS) Investors With Significant Losses to Take Action Before the November 2, 2026 Lead Plaintiff Deadline

  • Press releasePRNewswire

    Robbins LLP Reminds HIMS Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm Before November 2, 2026, for Information About Leading the Lawsuit Against Hims & Hers Health, Inc.

  • Press releasePRNewswire

    What Does Hims & Hers Health, Inc.'s 14.73% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline

  • Press releaseGlobe Newswire

    Deadline Alert: Hims & Hers Health, Inc. Investors Have Until November 2, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds

  • Press releaseGlobe Newswire

    HIMS 2-WEEK DEADLINE ALERT: Hims & Hers Health Faces Securities Fraud Class Action, Investors with Losses Encouraged to Contact Hagens Berman

Similar companies

Companies in the same industry as Hims & Hers Health

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.